Business Wire

DroneBase Secures $55 Million and Launches Next Stage of Advanced Inspection Under New Brand Zeitview

Share

Further cementing its market leadership in advanced inspection software for energy and infrastructure, DroneBase has secured $55 million in investment and rebranded as Zeitview. Led by Valor Equity Partners, an operational growth investment firm backing technology and technology-enabled companies, the round was followed by existing investors Union Square Ventures, Upfront Ventures, Euclidean Capital, Energy Transition Ventures, and Hearst Ventures. The new funding will support the company’s AI-enabled software and global footprint in advanced inspection solutions. This announcement caps a year of rapid growth within the renewable sector, including the launch of the North American Solar Scan (NASS), the first standardized set of solar asset ratings to ensure better oversight of U.S. solar power plants. Last year, Zeitview inspected 43 GW of solar capacity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005174/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere. (Graphic: Business Wire)

As Zeitview, the company will continue building advanced inspection software that delivers fast, accurate insights, lowers costs for asset owners and improves performance and longevity. The name change comes with the company’s increasingly diverse data capture tools: alongside rotary wing drones, Zeitview inspection professionals use crewed aircraft and smartphone technologies to create relevant, flexible solutions for clients. Its accompanying software platform with deep insights and analytics allows clients to easily view data results anywhere.

“We appreciate how important time is to our customers: on the one hand, they need immediate and accurate analysis about the health of their assets; on the other, they are building energy and infrastructure resources to last for decades,” said Dan Burton, founder and chief executive officer at Zeitview. “We are confident that our AI-enabled software solutions can deliver that immediate answer and a long-term home for our customers, while we are increasingly agnostic about what tool we use to capture the most accurate data. We are grateful that Valor recognizes the power of our comprehensive services to support customers to build, protect, and maintain infrastructure across multiple asset classes and around the world. They understand transformational energy and infrastructure software and embrace businesses that use technology to solve operationally complex problems.”

Valor’s partnership enables Zeitview to continue transforming the aerial inspection industry with emerging technologies and exclusive AI software. Valor’s hands-on operational track record with complex software-led companies bolsters Zeitview’s commitment to increasing data capture capabilities through automation.

“Valor has been a long-term champion of data science and analytics to improve businesses,” said Vivek Pattipati, Partner at Valor Equity Partners. “With Zeitview’s continued expansion of services and commitment to delivering accurate, real-time insights through advanced inspection software, we are naturally mission-aligned. We look forward to supporting Zeitview as they launch this rebrand and enter the next phase of aerial imagery and data solutions.”

Zeitview means “time view” and better captures the nature of the company’s services and mission to accelerate the transition to renewable energy and sustainable infrastructure. In addition to providing real-time data, Zeitview offers long-term solutions to track changes across a period of time for an asset. Zeitview remains committed to building on the foundation of market leadership in drone services while engaging new tools for the evolving needs of the customer base. With last year’s launch of the NASS, the ability to serve as a one-stop shop for asset owners across multiple markets, and a continually expanding network of pilots around the globe, Zeitview is trailblazing the future of information gathering without limits.

For more information on how Zeitview makes aerial inspection data accessible across markets, please visit www.zeitview.com.

About Zeitview

For global customers in energy and infrastructure, Zeitview builds advanced inspection software that delivers fast, accurate insights, lowers costs, and improves asset performance and longevity. We are second to none at partnering with our customers to achieve flexible, long-term solutions across their multiple asset classes. Trusted by the largest enterprises in the world, Zeitview is active in over 70 countries. Learn more at www.zeitview.com.

About Valor Equity Partners

Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development. For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale. Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries. For more information on Valor Equity Partners, please visit www.valorep.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technica Communications
Cait Caviness
zeitview@technica.inc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye